BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12114438)

  • 1. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
    Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
    Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.
    Shen L; Schroers R; Hammer J; Huang XF; Chen SY
    Cancer Immunol Immunother; 2004 May; 53(5):391-403. PubMed ID: 14624313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
    Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
    Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.
    Boesen A; Sundar K; Coico R
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1223-30. PubMed ID: 16210487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
    Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
    Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
    Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
    Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
    J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
    Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
    Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine.
    Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L
    Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.